Eikon Therapeutics
Eikon Therapeutics raises $350.7M Series D at $3B valuation
Eikon Therapeutics: Series D Funding Round
Eikon Therapeutics has successfully raised $350.7M in Series D funding, reaching a valuation of $3B.
Company Overview
Drug discovery using advanced microscopy
Funding Details
The Series D round was led by Andreessen Horowitz Bio, with participation from ARCH Venture Partners.
Company Information
- Headquarters: Hayward, CA
- Founded: 2019
- Employees: 200+
- Category: HealthTech
Investment
Eikon Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Andreessen Horowitz Bio: Verified investor in Series D
- ARCH Venture Partners: Verified investor in Series D
Company Info
Investors (2)
Share
Related Reports
Abridge Raises $150M Series C to Transform HealthTech
Abridge has secured $150M Series C in funding to accelerate growth and innovation in the healthtech sector. Medical AI scribe platform automatically documenting patient-provider conversations and generating clinical notes...
Innovaccer Raises $275M Series F to Transform HealthTech
Innovaccer has secured $275M Series F in funding to accelerate growth and innovation in the healthtech sector. Healthcare data platform unifying patient data and providing analytics for value-based care and population health manage...
Truveta Raises $95M Series B to Transform HealthTech
Truveta has secured $95M Series B in funding to accelerate growth and innovation in the healthtech sector. Healthcare data platform aggregating de-identified patient records to accelerate medical research and drug development...
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free